Immunome, Inc. and Zentalis Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug Conjugate (ADC) with best-in-class potential on track for IND submission in first quarter of 2025, and Zentalis' proprietary ADC platform technology. Under the terms of the deal, Zentalis will receive an up-front payment of $35 million in cash and Immunome common stock. Zentalis will be eligible to receive up to $275 million of milestone payments for ZPC-21 and the platform technology in addition to mid-to-high single-digit royalties.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.31 USD | -1.92% | +1.50% | +45.42% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
15.31 USD | -1.92% | +1.50% | 936M | ||
12.48 USD | +6.17% | -0.61% | 834M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.42% | 936M | |
+5.51% | 111B | |
+11.23% | 105B | |
-12.17% | 22.34B | |
-3.00% | 21.93B | |
-6.13% | 18.59B | |
-36.52% | 18.12B | |
-9.51% | 16.96B | |
+2.84% | 13.7B | |
+37.66% | 12.45B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate